| |
 |
Methods for delivering compounds into a cell |
| 7612033 |
Methods for delivering compounds into a cell
|
|
| Patent Drawings: | |
| Inventor: |
Unger, et al. |
| Date Issued: |
November 3, 2009 |
| Application: |
10/802,919 |
| Filed: |
March 18, 2004 |
| Inventors: |
Unger; Evan C. (Tucson, AZ)
McCreery; Thomas (Tucson, AZ)
|
| Assignee: |
ImaRx Pharmaceutical Corp. (Tucson, AZ) |
| Primary Examiner: |
Tsang; Cecilia |
| Assistant Examiner: |
Audet; Maury |
| Attorney Or Agent: |
DLA Piper LLP (US) |
| U.S. Class: |
514/2; 424/632 |
| Field Of Search: |
|
| International Class: |
A61K 38/00; A61K 33/34 |
| U.S Patent Documents: |
|
| Foreign Patent Documents: |
641363; B-30351/89; 25 21 003; 3803972; 195 41 679; 0 052 575; 0 107 559; 0 077 752; 0 243 947; 0 224 934; 0 231 091; 0 272 091; 0 320 433; 0 324 938; 0 338 971; 0 359 246; 357163; 0 361 894; 0 216 730; 0 467 031; 441468; 0 357 164; 0 458 745; 0 314 764; 0 554 213; 0 586 875; 0 614 656; 0 633 030; 0 727 225; 0 901 793; 2 700 952; 1044680; 2193095; 62 286534; SHO 63-60943; WO 80/02365; WO 82/01642; 85/01161; WO 85/02772; WO 86/00238; WO 86/01103; WO 89/02464; WO 89/05040; WO 90/01952; WO 90/04384; WO 90/04943; WO 91/00086; WO 91/03267; WO 91/09629; WO 91/12823; WO 91/15244; WO 91/18612; 92/05806; WO 92/10166; WO 92/11873; WO 92/15284; WO 92/17212; WO 92/17213; WO 92/17436; WO 92/17514; WO 92/21382; WO 92/22247; WO 92/22249; WO 92/22298; WO 93/00933; WO 93/05819; WO 93/06869; WO 93/13809; WO 93/17718; WO 93/19768; WO 93/20802; WO 94/00110; WO 94/06477; WO 94/07539; WO 94/09829; WO 84/02909; WO 94/16739; WO 94/21301; WO 94/21302; WO 94/28780; WO 94/28873; WO 95/03835; WO 95/06518; WO 95/07072; WO 95/23615; WO 95/24184; WO 95/32005; WO 95/32006; WO 96/04018; WO 96/09793; WO 96/36286; WO 96/40281; WO 96/40285; WO 98/00172; WO 98/04292; WO 99/13919 |
| Other References: |
Godbey, W.T. at al., "Recent Progress in Gene Delivery Using Non-viral Transfer Complexes", J Control Release 72 (2001), pp. 115-125. cited byother.
Hawiger J., "Noninvasive Intracellular Delivery of Functional Peptides and Proteins," Curr Opin Chem Biol. 1999, 3:89-94. cited by other.
Veach et al., Receptor/Transporter-independent Targeting of Functional Peptides Across the Plasma Membrane, J Biol Chem, vol. 279, No. 12, Mar. 19, 2004, pp. 11425-11431. cited by other.
Nomura et al., "US Contrast Enhancement of Hepatic Tumor with Helium Gas Microbubbles: A Preliminary Repor,t" Jpn. J. Med. Ultrasonics, vol. 18, No. 5 (1991) (full English language translation provided). cited by other.
Porter, et al., "Multifold Sonicated Dilutions of Albumin with Fifty Percent Dextrose Improve Left Ventricular Contrast Videointensity After Intravenous Injection in Human Beings," Journal of the American Society of Echocardiography, vol. 7, No. 5,pp. 465-471, Sep.-Oct. 1994. cited by other.
Porter, et al., "Noninvasive Identification of Acute Myocardial Ischemia and Reperfusion With Contrast Ultrasound Using Intravenous Perfluorpropane-Exposed Sonicated Dextrose Albumin," Journal of the American College of Cardiology, vol. 26, No. 1,pp. 33-40; 1995. cited by other.
Porter, et al., "Visually Discernible Myocardial Echocardiographic Contrast After Intravenous Injection of Sonicated Dextrose Albumin Microbubbles Containing High Molecular Weight, Less Soluble Gases," Journal of the American College of Cardiology,vol. 25, No. 2, pp. 509-515, Feb. 1995. cited by other.
Srinivasan, et al., "Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin," Antisense Research and Development, vol. 5, pp. 131-139, 1995. cited by other.
Xie, et al., "Acute Myocardial Ischemia and Reperfusion can be Visually Identified Non-invasively with Intravenous Perfluoropropane-Enhanced Sonicated Dextrose Albumin Ultrasound Contrast," Circulation, vol. 90, No. 4, Part 2, Abstract 2989, Oct.1994. cited by other.
Frezard, F. et al., "Fluorinated phosphatidylcholine-based liposomes: H+/Na+ permeability, active doxorubican encapsulation and stbility in human serum"Biochim et Biophys Acta, 1994, vol. 1194 (1), pp. 61-68. cited by other.
Gross, U. et al., "Phosholipid vesiculated fluorocarbons promising trend in blood substitutes" Biomat., Art. Cells & Immob. Biotech., 1992, vol. 20, (2-4) pp. 831-833. cited by other.
Riess, Jean G., "Fluorine in our arteries", New J. Chem., 1995, vol. 19 (8-9), pp. 891-909 (English Abstract). cited by other.
Riess, Jean G., "Introducing a new element fluorine-into the liposomal membrane" Journal of Liposome Research, 1995, vol. 5 (3) pp. 413-430. cited by other.
Santaella, C. et al., "Extended in vivo blood circulation time of fluorinated liposomes"FEBS Letters, 1993, vol. 336(3), pp. 481-484. cited by other.
Trevino, L, et al., "Incorporation of a perfluroalkylalkane (rfrh) into the phospholipid bilayer of dmpc liposomes results in greater encapsulation stability", Journal of Liposome Research., 1994, vol. 4 (2) pp. 1017-1028. cited by other.
Zarif L. et al., "Biodistribution and excretion of a mixed flurocarbon-hydrocarbon "dowel" emulsion as determined by 19-F NMR", Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, 1994, vol. 22,(4) pp. 1193-1198. cited by other.
Trevedi and Dickson (1995) "Liposome-mediated gene transfer into normal and dystrophin-deficient mouse myoblasts" J. Neurochem 64(5):2230-8 (Abstract only). cited by other.
Watson, A.J. (1995) "Review article: manipulation of cell death--the development of novel strategies for the treatment of gastrointestinal disease" Aliment. Pharmacol. Ther. 9(3):215-26 (Abstract only). cited by other.
Yla-Herttuala (1996) "Gene therapy for cardiovascular diseases" Ann. Med. 28(2):89-93 (Abstract only). cited by other.
Zabner (1996) "Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis" Clin. Invest. 97(6):1504-1511. cited by other.
Porter, T. R., et al., "Thrombolytic Enhancement with Perfluorocarbon-exposed Sonicated Dextrose Albumin Microbubbles", American Heart Journal, Nov. 1996, vol. 132, No. 5, pp. 964-968. cited by other.
Kinsler, L. E., et al., Fundamentals of Acoustics, 3.sup.rd Ed., 1982, 228-331. cited by other.
Meessen, H. (ed.), Microcirculation, Springer-Verlag, Berlin Heidelberg, New York, 1997, 44. cited by other.
Ring, J., et al., "Humanalbuminunvertraglichkeit: klinische und inununologische untersuchungen," Clinical Weekly, 1974, 52, 595-598 (Abstract-English). cited by other.
Robinson, et al., F.J. Fry (ed.), "Ultrasound: its applications in medicine and biology," Elsevier Scientific Publishing Company, 1978, vol. 3, Chap. XI, 593-596. cited by other.
Silbernagl, S., et al., "Pocket atlas of physiology," Georg Thieme Verlag, Stuttgart, New York, 1983, 156-157. cited by other.
Wells, P.N.T., "Pulse-echo methods," Biomedical Ultrasonics, Academic Press, 1977, 209-220. cited by other.
Ding, X.C., et al., "Scavenging effect of EDTA-fluorocarbon microspheres on .sup.210 lead," Chung Kuo Yao Li Hsueh Pao 1989, 10(5):473-475. (Abstract). cited by other.
Chortkoff, B.S. et al., "Pharmacokinetics Do Not Explain the Absence of an Anesthetic Effect of Perfluoropropane or Perfluoropentane," Anesth. Analog., 1994, 79, 234-237. cited by other.
Sharma, S.K. et al., "Emulsifcation Methods for Perfluorochemicals;" Drug Devel. Indust. Pharmacy, 1988, 14(15-17), 2371-2376. cited by other.
Tilcock, C. et al., "PEG-coated Lipid Vesicles with Encapsulated Technetium-99m as Blood Pool Agents for Nuclear Medicine," Nucl. Med. Biol., 1994, 2, 165-170. cited by other.
Tilcock, C. et al., ".sup.99m Tc-labeling of Lipid Vesicles Containing the Lipophilic Chelator PE-DTTA: Effect of Tin-to-chelate Ratio, Chelate Content and Surface Polymer on Labeling Efficiency and Biodistribution Behavior," Nucl. Med. Biol., 1994,1, 89-96. cited by other.
Zarif, L.et al., "Synergistic Stabilization of Perfluorocarbon-Pluronic F-68 Emulsion by Perfluoroalkylated Polyhydroxylated Surfactants," JAOCS, 1989, 66(10), 1515-1523. cited by other.
Jackson, B.A. et al., "Effect of ultrasound therapy on the repair of Achilles tendon injuries in rats", Med & Sci. In Sports & Exercise, 1991, 23(2), 171-176. cited by other.
Lejbkowicz, F. et al., "The response of normal and malignant cells to ultrasound in vitro", Ultrasound Med. Biol., 1993, 19(1), 75-82 (abstract only). cited by other.
Maxwell, L., "Therapeutic Ultrasound: Its Effects on the Cellular and Molecular Mechanisms of Inflammation and Repair", Physiotherapy, 1992, 78(6), 421-426. cited by other.
Tuncay, O. et at, "Expression of Genes Associated with Tissue Remodeling Upon Ultrasound Perturbation in the Gingival Fibroblast", J. Dental Res., 1996, 14, 143, Abstract No. 1007. cited by other.
Wang, S-J. et al., "Low Intensity Ultrasound Treatment Increases Strength in a Rat Femoral Fracture Model", J. Orthopaedic Res., 1994, 12, 40-47. cited by other.
Yang, K-H. et al., "Exposure to Low-Intensity Ultrasound Increases Aggrecan Gene Expression in a Rat Femur Fracture Model", J. Orthopaedic Res., 1996, 14, 802-809. cited by other.
Young, S.R. et al., "The Effect of Therapeutic Ultrasound on Angiogenesis", Ultrasound in Med. & Biol., 1990, 16(3), 261-269. cited by other.
Young, S.R. et al., "Effect of therapeutic ultrasound on the healing of full-thickness excised skin leasons", Ultrasonics, 1990, 28(3), 175-180. cited by other.
Hynynen et al., "The Usefulness of a Contrast Agent and Gradient Recalled Acquisition in a Steady-State Imaging Sequence for Magnetic Resonance Imaging-Guided Noninvasive Ultrasound Surgery", Investigative Radiology, 1994, 29(10), 897-903. cited byother.
Hautanen, A., et al., "Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor," J Biol. Chem., 1989, 264(3), 1437-1442. cited by other.
Takeuchi, M., et al., "Enhanced visualization of intravascular thrombus with the use of a thrombus targeting ultrasound contrast agent (MRX408): Evidence from in vivo experimental echocardiographic studies," J. Am. College of Cardiology, 1998,81(12), 1 page, Abstract XP-000952675. cited by other.
Unger, E.C., et al., "In vitrostudies of a new thrombus-specific ultrasound contrast agent," J. of Cardiology, 1998, 81(12), 58G-61G, Abstract XP-002087505. cited by other.
Wu, Y., et al., "Binding and lysing of blood clots using MRX-408," Investigate Radiology, 1998, 33(12), 880-885. cited by other.
Lindner et al., "Myocardial Perfusion Characteristics and Hemodynamic Profile of MRX-115, a Venous Echocardiographic Contrast Agent, During Acute Myocardial Infarction", J. Am. Soc. Echocardiography, 1998, 11(1), 36-46. cited by other.
Regen et al., "Polymerized Phosphatidylcholine Vesicles. Synthesis and Characterization", J. Am. Chem. Soc., 1982, 104(3), 191-195. cited by other.
Wei et al., "Quantification of Myocardial Blood Flow with Ultrasound-Induced Destruction of Microbubbles Administered as a Constant Venous Infusion", Circulation, 1998, 97, 473-483. cited by other.
Nomura et al., "US Contrast Enhancement of Hepatic Tumor with Helium Gas Microbubbles: A Preliminary Report", Jpn. J. Med. Ultrasonics, 1991, 18(5), (Japanese with English language abstract). cited by other.
Reexamination of U.S. Patent No. 5,527,521, issued May 16, 2003, Reexam Control No. 90/004,719. cited by other.
Reexamination of U.S. Patent No. 5,547,656, issued Sep. 13, 2000, Reexam Control No. 90/004,720. cited by other.
Desir et al., "Assessment of regional myocardial perfusion with myocardial contrast echocardiography in a canine model of varying degrees of coronary stenosis", Am. Heart J., Jan. 1994, 127(1), 56-63. cited by other.
Sekins et al., "Lung Cancer Hyperthermia via Ultrasound and PFC Liquids", Published in Proceedings of 5th International Symposium on Hyperthermic Oncology, Kyoto, Japan, Aug. 29-Sep. 3, 1998, 3 pages. cited by other.
Pietersen, "A New Warning System for Fires of Electrical Origin", CERN European Organization for Nuclear Research, Health and Safety Division, Mar. 1977, 1-5. cited by other.
Villanueva et al., "Characterization of Spatial Patters of Flow Within the Reperfused Myocardium by Myocardial Contrast Echocardiography", Circulation, vol. 88, No. 6, pp. 2596-2606 (Dec. 1993). cited by other.
Nabel et al., "Combined Experience from Phase I Studies with Allovectin-7, a Direct Gene Transfer Immunotherapeutic in Patients with Metastatic Solid Tumors", Proceed. ASCO, Mar. 14, 1995, 14, 226, (31st Annual Meeting of the American Society ofClinical Oncology, May 20-23, 1995) (Abstract No. 582). cited by other.
Rubin et al., "Phase I Study of Immunotherapy of Hepatic Metastasis of Colorectal Carcinoma by Direct Gene Transfer", Proceed. ASCO, Mar. 14, 1995, 14, 228, (31st Annual Meeting of the American Society of Clinical Oncology, May 20-23, 1995)(Abstract No. 589). cited by other.
Fitzpatrick, et al., "Metal Ion Catalyzed Decarboxylation: Kinetics and Mechanism of the Oxidative Decarboxylation of Copper (II) Complexes of Aminomalonic Acid in Aqueous Solution", Inorganic Chemistry, vol. 13, No. 3, pp. 568-574 (1974). cited byother.
Thanassi, "Aminomalonic Acid: Spontaneous Decarboxy-lation and Reaction with 5-Deoxypyridoxal", Bio-chemistry, vol. 9, No. 3, pp. 525-532 (1970). cited by other.
Stelmashok et al., Koordinatsionnaya Khimiya, vol. 3, No. 4, pp. 524-527 (1977) (Russian and English language versions). cited by other.
Mayhew et al., "High-Pressure Continuous-Flow System for Drug Entrapment in Liposomes", Methods in Enzymology, vol. 149, pp. 64-77 (1987). cited by other.
Mayhew et al., "Characterization of Liposomes Prepared Using a Microemulsifier", Biochimica et Biophysica Acta, vol. 775, pp. 169-174 (1984). cited by other.
Hope et al.,"Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size Distribution, Trapped Volume, and Ability to Maintain a Membrane Potential", Biochimica et Biophysica Acta, 812: 55-65 (1985). cited byother.
Mayer et al., "Vesicles of Variable Size Produced by a Rapid Extrusion Procedure", Biochimica et Biophysica Acta, vol. 858, pp. 161-168 (1986). cited by other.
Cheng, et al., "The Production and Evaluation of Contrast-Carrying Liposomes Made with an Automatic High Pressure System", Investigative Radiology, vol. 22, pp. 47-55 (1987). cited by other.
Jain, et al., Introduction to Biological Membranes, Ch. 9, pp. 192-231 (J. Wiley and Sons, N.Y. 1980). cited by other.
Sigel, H., ed., Metal Ions in Biological Systems: Antibiotics and Their Complexes, vol. 19 (Marcel Dekker, N.Y. 1985). cited by other.
Nayar et al., "Generation of Large Unilamellar Vesicles From Long-chain Saturated Phosphatidylcholines by Extrusion Technique", Biochimica et Biophysica Acta, vol. 986, pp. 200-206 (1989). cited by other.
Hope et al., "Generation of Multilamellar and Unilamellar Phospholipid Vesicles", Chemistry and Physics of Lipids, vol. 40, pp. 89-107 (1986). cited by other.
Mattrey et al., "Perfluorochemicals as US Contrast Agents for Tumor-Imaging and Hepatosplenography: Preliminary Clinical Results", Radiology, vol. 163, pp. 339-343 (1987). cited by other.
Mattrey et al., "Perfluoroctylbromide: A Liver/Spleen-Specific and Tumor Imaging Ultrasound Contrast Material", Radiology, vol. 145, pp. 759-762 (1982). cited by other.
Keller et al., "Successful Left Ventricular Opacification Following Peripheral Venous Injection of Sonicated Contrast Agent: An Experimental Evaluation", LV Contrast Echocardiography, vol. 114, No. 3, pp. 570-575 (1987). cited by other.
Feinstein et al., "Two-Dimensional Contrast Echocar-diography, I: In Vitro Development and Quantitative Analysis of Echo Contrast Agents", JACC, vol. 3, No. 1, pp. 14-20 (1984). cited by other.
Ten Cate et al., "Two-Dimensional Contrast Echocar-diography, II: Transpulmonary Studies", JACC, vol. 3, No. 1, pp. 21-27 (1984). cited by other.
Unger et al., "Hepatic Metastases: Liposomal Gd-DTPA-enhanced MR Imaging", Radiology, vol. 171, pp. 81-85 (1989). cited by other.
Deamer et al., "Permeability of Lipid Bilayers to Water and Ionic Solutes", Chemistry and Physics of Lipids, vol. 40, pp. 167-188 (1986). cited by other.
Gutknecht et al., "Diffusion of Carbon Dioxide Through Lipid Bilayer Membranes: Effect of Carbonic Anhydrase, Bicarbonate, and Unstirred Layers", Chemical Abstracts, 87:34772q (1977). cited by other.
Scarpa et al., "Cation Permeability of Liposomes as a Function of the Chemical Composition of the Lipid Bilayers", Biochimica et Biophysica Acta, vol. 241, pp. 789-797 (1971). cited by other.
MacNaughton et al., "Effects of Gaseous Anesthetics and Inert Gases on the Phase Transition in Smectic Mesophases of Dipalmitoyl Phosphatidylcholine", Biochimica et Biophysica Acta, vol. 597, pp. 193-198 (1980). cited by other.
Tilcock et al., "Liposomal Gd-DTPA: Preparation and Characterization of Relaxivity", Radiology, vol. 171, pp. 77-80 (1989). cited by other.
Mann et al., "Formation of Iron Oxides in Unilamellar Vesicles", Journal of Colloid and Interface Science, vol. 122, No. 2, pp. 326-335 (1988). cited by other.
Anderson et al., "Manganese (III) Complexes in Oxidative Decarboxylation of Acids", J. Am. Chem. Soc., vol. 92, 2450-2460 (1970). cited by other.
Muhlradt et al., "Vitamin B6 Analogs: An Improved Synthesis of 5-Deoxypyridoxal", New Compounds, vol. 10, pp. 129-130 (1967). cited by other.
Chapman D., "Physiochemical Properties of Phospholipids and Lipid Water Systems", Liposome Technology, Gregoriadis, G., ed., vol. 1, pp. 1-19 (CRC Press, Boca Raton, FL, 1984). cited by other.
Violante et al., "Particulate Suspensions as Ultrasonic Contrast Agents for Liver and Spleen", Inv. Rad., vol. 23, pp. S294-S297, Sep. 1988. cited by other.
Fritzsch et al., "Preclinical and Clinical Results with an Ultrasonic Contrast Agent", Inv. Rad., vol. 23, pp. S302-S305, Sep. 1988. cited by other.
Brochure, Experience, Sonicator.TM., Heat Systems-Ultrasonics, Inc. (1987). cited by other.
M. Ostro, "Liposomes", Marcel Dekker, New York, pp. 102-103 (1983). cited by other.
Fukuda et al., "Polymer-Encased Vesicles Derived from Diotadecyldimethylammonium Methacrylate", J. Am. Chem. Soc., vol. 108, pp. 2321-2327 (1986). cited by other.
Regen, "Polymerized Vesicles", J. Am. Chem. Soc., vol. 102, pp. 6638-6640 (1989). cited by other.
Rose, A. and Rose, E., "The Condensed Chemical Dictionary", Reinhold Publishing, New York, pp. 728 and 743 (1966). cited by other.
A.G. Belykh, Farmakol Toksikol. (MOSC), vol. 44(3), pp. 322-326 (1981) (abstract). cited by other.
J. Vion-Dury et al., J. Pharmacol. Exper. Ther., vol. 250(3), pp. 1113-1118 (1989) (abstract). cited by other.
M.R. Zalutsky et al., Invest. Radiol., vol. 22(2), pp. 141-147 (1987) (abstract). cited by other.
Crowe et al., Archives of Biochemistry and Biophysics, vol. 242, pp. 240-247 (1985). cited by other.
Crowe et al., Archives of Biochemistry and Biophysics, vol. 220, pp. 477-484 (1983). cited by other.
Dorland's Illustrated Medical Dictionary, p. 946, 27th ed. (W.B. Saunders Company, Philadelphia 1988). cited by other.
Liposome Technology, Gregoriadis, G., ed., vol. I, pp. 1-18, 29-35, 51-65 and 79-107 (CRC Press Inc., Boca Raton, FL, (1984). cited by other.
Madden et al., Chemistry and Physics of Lipids, vol. 53, pp. 37-46 (1990). cited by other.
Sinkula et al., J. Pharm. Sci., vol. 64, pp. 181-210 (1975). cited by other.
Shiina et al., "Hyperthermiaby Low-frequency Synthesized Ultrasound", IEEE Engineering, pp. 879-880, vol. 2 (1988) (abstract). cited by other.
McAvoy et al., IEEE Engineering, Ultrasonics Symposium Proceedings, vol. 2, pp. 677-1248 (1989) (abstract). cited by other.
Chapman et al., "Biomembrane Phase Transitions", J. Biol. Chem., 1974, 249:2512-2521. cited by other.
Hug et al., "Liposomes for the Transformation of Eukaryotic Cells", Biochimica et Biophysica Acta, 1991, 1097:1-17. cited by other.
Marsh, CRC Handbook of Lipid Bilayers (CRC Press, Boca Raton, FL 1990) pp. 139-141. cited by other.
Szoka et al., "Procedure for Preparation of Liposomes With Large Internal Aqueous Space . . . ", Proc. Natl. Acad. Sci. 1978, 75:4194-4198. cited by other.
Acoustic Imaging; AI5200; Convex Curved Linear Array Ultrasound Transducers Operator's Manual, Nov. 20, 1989, 4700-0003-1C, p. 4. cited by other.
Bangham et al., "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids", J. Mol. Biol., 1965, 13:238-252. cited by other.
Carson et al., Ultrasound in Med. & Biol. 3, 1978, 341-350. cited by other.
Kost et al., Polymers in Medicine II: Biomedical and Pharmaceutical Applications, "Ultrasonic Modulated Drug Delivery Systems", Chiellini et al., ed., (Plenum Press, New York and London), pp. 387-396 (1985). cited by other.
deGier et al., "Relations Between Liposomes and Biomembranes", Annals of the New York Academy of Sciences, 1978, 308:85-99. cited by other.
Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", Proc. Natl. Acad. Sci., 1987, 84:7413-7417. cited by other.
Gabizon et al., "Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors", Proc. Natl. Acad. Sci., 1988, 85:6949-6953. cited by other.
Garelli, et al., Biochimica et Biophysica Acta, vol. 1127:41-48 (1992). cited by other.
Kawai et al., "New Procedure for DNA Transfection with Polycation and Dimethyl Sulfoxide", Molecular and Cellular Biology, 1984, 4:1172-1174. cited by other.
Kuo et al., "Metallocene Antitumor Agents. Solution and Solid-State Molybdenocene Coordination . . . ", J. Am. Chem. Soc., 1991, 113:9027-9045. cited by other.
Mammalian Cell Biotechnology: A Practical Approach, M. Butler, 1991 (Oxford University Press, New York), p. 57-70. cited by other.
Mathiowitz et al., "Photochemical Rupture of Microcapsules: A Model System", Journal of Applied Polymer Science, 1981, 26:809-822. cited by other.
May et al., "Cationic Liposomes Enable Bovine Herpesvirus Type 2 DNA to Infect Cells", Acta virol., 1991, 35:107. cited by other.
Poznansky et al., "Biologica Approaches to the Controlled Delivery of Drugs: A Critical Review", Pharmacol, Rev., 1984, 36:277-336. cited by other.
Sato et al., "Recent Aspects in the Use of Liposomes in Biotechnology and Medicine", Prog. Lipid Res. 1992, 4:345-372. cited by other.
Simons et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo", Nature, 1992, 359:67-70. cited by other.
Thompson, Larry, "At Age 2, Gene Therapy Enters a Growth Phase", Science 1992, 258:744-746. cited by other.
Trubetskoy et al. "Cationic liposomes enhance targeted delivery and expression of exogenous DNA . . . ", Biochimica et Biophysica Acta 1992, 131:311-313. cited by other.
Umemura et al., "Studies on Sonodynamic Cancer Therapy", IEEE, 1992, O-7803-0785, pp. 354-355. cited by other.
Williams, "Human Gene Therapy: Searching for Better Vectors", ASM News [American Society for Microbology] 1992, 58:67-69. cited by other.
Woodle et al., "Versatility in lipid compositions showing prolonged circulation . . . ", Biochimica et Biophysica Acta 1992, 1105:193-200. cited by other.
Zhou et al., "Targeted delivery of DNA by liposomes and polymers", J. of Controlled Release 1992, 19:269-274. cited by other.
Mathiowitz et al., "Polyanhydride Microspheres as Drug Carriers", Journal of Applied Polymer Science, vol. 35, pp. 755-774 (1988). cited by other.
Sankaram et al., "Cholesterol-Induced Fluid-Phase Immiscibility in Membranes", Proc. Natl. Acad. Sci., vol. 88, pp. 8686-8690 (1991). cited by other.
Scientific Apparatus Catalog 92/93 (VWR Scientific, 1991), "Syringes", pp. 1511-1513; "Filtration, Syringe Filters", pp. 766-768; "Filtration, Membranes", pp. 750-753; "Filtration, Filter Holders", p. 744. cited by other.
Gramiak et al., Radiology, "Detection of Intracardiac Blood Flow by Pulsed Echo-Ranging", pp. 415-418 (1971). cited by other.
Feigenbaum et al., Circulation, "Identification of Ultrasound Echoes from the Left Ventricle by Use of Intracardiac Injections of Indocyanine Green", vol. XL1, pp. 615-621 (1970). cited by other.
Santaella, et al., FEBS 13463, "Extended In Vivo Blood Circulation Time of Fluorinated Liposomes", vol. 336, No. 3, pp. 481-484 (1993). cited by other.
Brown and Langer, Annual Review Medicine, 1988, 39:221 29, Annual Review, Inc., "Transdermal Delivery of Drugs", pp. 221-229. cited by other.
Moseley, et al., Microbubbles: A Novel MR Susceptibility Contrast Agent, abstract, 1991 Napa, California Meeting of the Society for Magnetic Resonance in Medicine. cited by other.
Ter-Pogossia Tomography, Kee, et al., n, "Physical Principles and Instrumentation", Computed Body eds., Raven Press, New York, Chapter 1, pp. 1-7 (1988). cited by other.
Aronberg, "Techniques", Computed Body Tomography, Kee, et al., eds., Raven Press, New York, Chapter 2, pp. 9-36. cited by other.
Miller, Ultrasonics (Sep. 1981), "Ultrasonic detection of resonant cavitation bubbles in a flow tube by their second-harmonic emissions," pp. 217-224. cited by other.
Dittrich, "Cardiac Muscle Ischemia and Infarction", The Second Annual International Symposium on Contrast Agents in Diagnostic Ultrasound, Atlantic City, NJ (May 7, 1996) (abstract). cited by other.
Pantely, "Intravenous Contrast Echocardiography-Tissue Imaging & Quantification of Coronary Blood Flow", The Second Annual International Symposium on Contrast Agents in Diagnostic Ultrasound, Atlantic City, NJ (May 7, 1996) (abstract). cited byother.
Keown, W. et al., "Methods for Introducing DNA into Mammalian Cells", Methods in Enzymology vol. 185 "Gene Expression Technology", Goeddel, D., ed., Academic Press, Inc., New York, 1991, pp. 527-537. cited by other.
Wyber, J.A. et al., "The Introduction of Macromolecules into Cells Using Ultrasound", Pharmaceutical Research Sep. 1995 (Supplement), 12(9), S-96, Biotec 2069. cited by other.
"Imarx' Ultrasound Agent Ready for Phase II Trials", Clinica World Medical Device News Jun. 26, 1995, p. 17. cited by other.
Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor", J. Biol. Chem., 1991, 266(18), 11947-11954. cited by other.
Siegel et al., "Percutaneous Coronary Ultrasonic Angioplasty: Initial Clinical Experience", Eur. Heart J., 1993, 14, 78, abstract 588. cited by other.
Riessen et al., "Percutaneous arterial gene transfer using pure DNA applied to a hydrogel-coated angioplasty balloon", Eur. Heart J., 1993, 14, 78, abstract 590. cited by other.
Rennie et al. (eds.), 1996 Scientific American, Sep. 1996, 126-132. cited by other.
Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", Dec. 7, 1995. cited by other.
Schutt et al., "Osmotically Stabilized Microbubble Sonographic Contrast Agents", Acad. Radiol., vol. 3, Suppl. 2, pp. S188-S190 (Aug. 1996). cited by other.
Frezard, et al., "Permeability and stability in buffer and in human serum of fluorinated phospholipid-based liposomes", Biochimica et Biophysica Acta, 1192, pp. 61-70 (1994). cited by other.
Frezard, et al., "Fluorinated Phospholipid-Based Vesicles as Potential Drug Carriers: Encapsulation/Sustaining of Drugs and Stability in Human Serum", Art, Cells, Blood Subs., and Immob. Biotech., 22(4), pp. 1403-1408 (1994). cited by other.
Chang et al., "Semipermeable Aqueous Microcapsules", Canadian J. Of Phys. And Pharm., 1966, 44, 115-128. cited by other.
Chang, "Semipermeable Microcapsules", Science, 1964, 146, 524-525. cited by other.
Deasy, Microencapsulation and Related Drug Processes, 1983, vol. 20, Chs. 9 and 10, 195-240 (Marcel Dekker, Inc., NY). cited by other.
Yeung et al., "Preparation of Microencapsulated Liposomes", J. Microencapsulation, 1988, 5, 331-337. cited by other.
Mattrey et al., Gas Emulsions as Ultrasound Contrast Agents; Preliminary Results in Rabbits and Dogs, Investigative Radiology, vol. 29, June Supp. 2, pp. S139-S141, 1994. cited by other.
Meltzer et al., Transmission of Ultrasonic Contrast Through the Lungs, Ultrasound in Med. & Biol., vol. 7, No. 4, 377-384, 1981. cited by other.
PR Newswire, Apr. 1, 1986. cited by other.
Swanson et al., Chapter 22, "Enhancement Agents for Ultrasound: Fundamentals", Pharmaceuticals In Medical Imaging, pp. 682-687 (1990). cited by other.
Ophir et al., "Contrast Agents in Diagnostic Ultrasound", Ultrasound in Med. & Biol., vol. 15, No. 4, pp. 319-333 (1989). cited by other.
Jacobs, "Intraocular gas measurement using A-scan ultrasound", Current Eye Research, vol. 5, No. 8, pp. 575-578 (1986). cited by other.
Lincoff et al., "Intravitreal Expansion of Perfluorocarbon Bubbles", Arch. Ophthalmol., 1980, 98, 1646. cited by other.
Lincoff et al., "Intravitreal Longevity of Three Perfluorocarbon Gases", Arch. Ophthalmol., 1980, 98, 1610-1611. cited by other.
Lincoff et al., "The Perfluorocarbon Gases in the Treatment of Retinal Detachment", Ophthalmology, 1983, 90(5), 546-551. cited by other.
Gardner et al., "A Survey of Intraocular Gas Use in North America", Arch. Ophthalmol., 1988, 106, 1188-1189. cited by other.
Unger et al., "Liposomal MR Contrast Agents", J. Liposome Research, 1994, 4(2), 811-834. cited by other.
Feinstein, Steven B., "Myocardial Perfusion Imaging: Contrast Echocardiography Today and Tomorrow," Journal of the American College of Cardiology, 8(1):251-253 (1986). cited by other.
Keller et al., "The Behavior of Sonicated Albumin Microbubbles Within the Microcirulation: A Basis for Their Use During Myocardial Contrast Echocardiography", Circulation Res., 65(2):458-465 (1989). cited by other.
Lincoff et al., "Perfluoro-n-butane: A Gas for Maximum Duration Retinal Tamponade," Arch Ophthalmology, 101:460-462 (1983). cited by other.
Remington's Pharmaceutical Sciences, John Hoover, managing ed., Mack Publishing Company, Easton, PA, pp. 295-298; 736; 1242-1244 (1975). cited by other.
Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington, D.C. and The Pharmaceutical Society of Great Britain, London, England, pp. 181-183 (1986). cited by other.
Barnhart et al., "Characteristics of Albunex.TM.: Air-Filled Microspheres for Echocardiography Contrast Enhancement," Investigative Radiology, 25:S162-164, Sep. 1990. cited by other.
Levene et al., "Characterization of Albunex.TM.," J. Acoust. Soc. Am., 87(Suppl.1):569-70, 1990. cited by other.
Miller et al., "Physiochemical Approaches to the Mode of Action of General Anesthetics," J. Amer. Soc. Anesthesiologists, 36(4):339-351 (1972). cited by other.
"Properties and Applications of the `Freon` Fluorocarbons" in DuPont Freon Technical Bulletin B-2 (E.I. DuPont de Nemours and Company, Wilmington, DE), pp. 1-11 (1964). cited by other.
"`Freon` Fluorocarbons: Properties and Applications" in DuPont Technical Bulletin G-1 (E.I. DuPont de Nemours and Company, Wilmington, DE), pp. 1-10 (1987). cited by other.
"Encyclopedia of Polymer Science and Engineering," John Wiley & Sons, New York, 1:164-169 (1985). cited by other.
"Concise Encyclopedia of Polymer Science and Engineering," J. Kroschwitz, ed., John Wiley & Sons, New York, pp. 12-13 (1990). cited by other.
Wheatley et al., "Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles," Biomaterials, 11:713-717 (1990). cited by other.
Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing", Mol. Cell Biol., 1986, 6(9), 3232-3239. cited by other.
Arai et al., Complete Nucleotide Sequence of the Chromosomal Gene for Human IL-4 and its Expression, J. Immunol., 1989, 142(1), 274-282. cited by other.
Axel et al., "Transformation of Mammalian Cells with Prokaryotic and Eukaryotic Genes", J. Supramol. Struct., 1979, 8 (Supp. 3), 41. cited by other.
Barnes et al., "Gene Therapy and Ovarian Cancer: A Review", Obstetrics and Gynecology, 1997, 89(1), 145-155. cited by other.
Bratty et al., "The hammerhead RNA domain, a model ribozyme", Biochim. Biophys. Acta, 1993, 1216, 345-349. cited by other.
Delius et al., "Extracorporeal Shock Waves for Gene Therapy", Lancet, 1995, 345, 1377. cited by other.
Fiddes et al., "Structure of genes for human growth hormone and chorionic somatomammotripin", Proc. Natl. Acad. Sci. USA, 1979, 76(9), 4294-4298. cited by other.
Foecking et al., "Powerful and versatile enhancer-promoter unit for mammalian expression vectors", Gene, 1986, 45, 101-105. cited by other.
Gambihler et al., "Permeabilization of the Plasma Membrane of L1210 Mouse Leukemia Cells Using Lithotripter Shock Waves", J. Membr. Biol., 1994, 141, 267-275. cited by other.
Giddings et al., "Selective Expression and Developmental Regulation of the Ancestral Rat Insulin II Gene in Fetal Liver", Mol. Endocrinol., 1990, 4(9), 1363-1369. cited by other.
Higuchi et al., "Characterization of Mutations in the Factor VIII Gene by Direct Sequencing of Amplified Genomic DNA", Genomics, 1990, 6, 65-71. cited by other.
Kawabata et al., "Effect of second-harmonic superimposition in efficient induction of sonochemical effect", Ultrasonics Sonochem., 1996, 3, 1-5. cited by other.
Lauer et al., "Towards a New Gene Transfer System: Shock Wave-Mediated DNA Transfer", J. Cell Biochem., 1994, (Supp. 18A), 226. cited by other.
Maier et al., "Thymocytes Express a mRNA that is Identical to Hypothalamic Luteinizing Hormone-Releaseing Hormone mRNA", Cell Mol. Neurobiol., 1992, 12(5), 447-454. cited by other.
Mobley et al., "Low Energy Lithotripsy with the Lithostar: Treatment Results with 19,962 Genal and ureteral Calculi", J. Urol., 1993, 149, 1419-1424. cited by other.
McKay, "Structure and function of the hammerhead ribozyme: An unfinished story", RNA, 1996, 2, 395-403. cited by other.
Mitsudomi et al., "Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients with Lung Cancer", Chest, 1993, 104(2), 362-365. cited by other.
Rubin et al., 31st Annual Meeting of the American Society of Clinical Oncology, May 20-23, 1995, (Abstract No. 589). cited by other.
Thompson, "At Age 2, Gene Therapy Enters a Growth Phase", Science, 1992, 258, 744-746. cited by other.
Trucco et al., "Rapid Detection of IDDM Susceptibility with HLA-DQ .beta.-Alleles as Markers", Diabetes, 1989, 38, 1617-1622. cited by other.
Tsujimoto et al., "Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma", Proc. Natl. Acad. Sci. USA, 1986, 83, 5214-5218. cited by other.
Zhang et al., "Ultrasonic Direct Gene Transfer the Establishment of High Efficiency Genetic Transformation System for Tobacco", Sci. Agric. Sin., 1991, 24, 83-89 (Abstract attached). cited by other. |
|
| Abstract: |
The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired. |
| Claim: |
What is claimed is:
1. A method for delivering a protein into a cell in vivo, comprising: (a) forming a plurality of protein-halide vesicles comprising the protein to be delivered and an organichalide incorporated in the core of the vesicles; and (b) administering the protein-halide vesicles to the cell, wherein the organic halide is selected from the group consisting of 1-bromo-nonafluorobutane, perfluorooctyliodide, perfluoroocytlbromide,1-chloro-1-fluoro-1-bromomethane, 1,1,1-trichloro-2,2,2-trifluoroethane, 1,2-dichloro-2,2-difluoroethane, 1,1-dichloro-1,2-difluoroethane, 1,2-dichloro-1,1,3-trifluoropropane, 1-bromoperfluorobutane, 2-iodo-1,1,1-trifluoroethane, 5-bromovaleryl chloride,1,3-dichlorotetrafluoroacetone, 1-bromo-1,1,2,3,3,3-hexafluoropropane, 2-chloro-1,1,1,4,4,4-hexafluoro-2-butene, 2-chloropentafluoro-1,3-butadiene, iodotrifluoroethylene, 1,1,2-trifluoro-2-chloroethane, 1,2-difluorochloroethane,1,1-difluoro-2-chloroethane, 1,1-dichlorofluoroethane, heptafluoro-2-iodopropane, bromotrifluoroethane, chlorotrifluoromethane, dibromofluoromethane, chloropentafluoroethane, bromochlorodifluoromethane, dichloro-1,1,2,2-tetrafluoroethane,1,1,1,3,3-pentafluoropentane, perfluorotributylamine, perfluorotripropylamine, 2,2,2-trifluoroethylacrylate, 3-(trifluoromethoxy)-acetophenone, 1,1,2,2,3,3,4,4-octafluorobutane, 1,1,1,3,3-pentafluorobutane, 1-fluorobutane,1,1,2,2,3,3,4,4-octafluorobutane, 1,1,1,3,3-pentafluorobutane, tetradecaperfluoroheptane, dodecaperfluorocyclohexane, perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, perfluoroheptane,perfluorooctane, perfluorononane, perfluorodecane, perfluorododecane, perfluoro-2-methyl-2-pentene, perfluorocyclohexane, perfluoropropylene, perfluorocyclobutane, perfluoro-2-butyne, perfluoro-2-butene, perfluorobuta-1,3-diene, perfluorobutylethylether, bis(perfluoroisopropyl) ether, bis(perfluoropropyl) ether, perfluoromethyl tetrahydrofuran, perfluoro t-butyl methyl ether, perfluoro isobutyl methyl ether; perfluoro n-butyl methyl ether, perfluoro isopropyl ethyl ether, perfluoro n-propyl ethylether, perfluoro cyclobutyl methyl ether, perfluoro cyclopropyl ethyl ether, perfluoro isopropyl methyl ether, perfluoro n-propyl methyl ether, perfluoro diethyl ether, perfluoro cyclopropyl methyl ether, perfluoro methyl ethyl ether, and perfluorodimethyl ether, wherein the path of administering of the protein-halide composition to the cell is selected from a group consisting of the administering through a cell membrane, cell wall, and nuclear membrane, or any combination thereof, to achieve theintracellular delivery of the protein thereby.
2. The method of claim 1, wherein the organic halide is selected from the group consisting of 1-bromo-nonafluorobutane, 1,1,1,3,3-pentafluoropentane, perfluorohexane, perfluorocyclohexane, 1-bromo-1,1,2,3,3,3-hexafluoropropane,heptafluoro-2-iodopropane, 1,1,2,2,3,3,4,4-octafluorobutane, 1-fluorobutane, tetradecaperfluoroheptane, and dodecaperfluorocyclohexane.
3. The method of claim 1, wherein the organic halide is selected from the group consisting of perfluorohexane and perfluorocyclohexane.
4. The method of claim 1, wherein the protein is selected from the group consisting of albumin, collagen, polyarginine, polylysine, polyhistidine, .gamma.-globulin, and .beta.-globulin.
5. The method of claim 1, wherein the protein is a cationic protein.
6. The method of claim 5, wherein the cationic protein is selected from the group consisting of polylysine and polyethyleneimine.
7. The method of claim 1, further comprising applying ultrasound to the cell.
8. The method of claim 7, wherein the ultrasound is applied at a frequency between about 40 kHz and 25 MHz, and an energy level between about 500 mW/cm.sup.2 and 10 W/cm.sup.2.
9. The method of claim 7, wherein the ultrasound is applied at a frequency between about 200 kHz and 500 kHz, and the energy level is between about 200 mW/cm.sup.2 and 500 W/cm.sup.2.
10. The method of claim 7, wherein the ultrasound is applied at a frequency between about 1 MHz and 20 MHz, and the energy level is between about 100 W/cm.sup.2 and 200 W/cm.sup.2.
11. The method of claim 10, wherein the ultrasound is applied at a duty cycle between about 1% and 100% of the treatment time.
12. The method of claim 7, wherein the protein and the ultrasound are administered and applied simultaneously. |
| Description: |
|
|
|
|
